Who is Dr. Tom Chang MD to the Field of Ophthalmology?

Tom Chang MD has been in practice in the field of Ophthalmology for more than 20 years. He specializes in general ophthalmology and retinal diseases. Dr. Chang received his MD from the University of Toronto Medical School. His residency training in ophthalmology was obtained at the University of Western Ontario. To continue his studies in ophthalmology, Dr. Chang completed three fellowships in retinal diseases.

 

Dr. Chang’s Retinal Disease Fellowships

 

1)At the Wilmer Eye Institute at Johns Hopkins University, he completed a fellowship in ophthalmic pathology.

2)At the Bascom Palmer Eye Institute of the University of Miami, he studied with Dr. Donald Gass and received his fellowship in macular disease.

3)He received his fellowship for vitreoretinal surgery at Emory University in Atlanta, Georgia.

 

Teaching Ophthalmology

 

1)For five years, Tom Chang MD taught ophthalmology as an assistant professor at the University of British Columbia immediately after completing his fellowships.

2)For the next six years, Tom Chang MD was the Director of the Retina Fellowship and the Associate Professor of Ophthalmology at the Doheny Eye Institute.

3)He went a step further when he decided ion 2005 to found the Retina Institute of California.

 

Ground-breaking Surgeries

 

As a part of the team, Dr. Chang performed the world’s first surgical implantation of stem cell treatment for dry macular degeneration. This procedure was done in collaboration with the Johnson & Johnson Stem Cell organization. The doctors at his Retina Institute of California have performed more sub-retinal stem cell surgeries than anyone else in the world.

 

Dr. Chang serves on the scientific advisory boards of Fortune 500 companies and has served as the team ophthalmologist for the Vancouver Grizzlies. He has written more than 50 peer-reviewed publications and lectured in at least 15 countries. He is interested in both the research and the clinical. Drug delivery systems and health outcome assessments lie at the top of his research interests and macular degeneration is at the top of his clinical interests.